CoChat

Digital Management of Early-Onset Type 2 Diabetes: Empowerment, Challenges, and Future Outlook

Open access
Guo, Li-Jun, Low, Kah-Seng, Tae, Sok-Kun, Lim, Lee-Ling · 2026 · Current Diabetes Reports

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index; none of the 113 sources its claims cite is checked for support yet.

Abstract

Purpose of Review: Early-onset type 2 diabetes (EOT2D), defined as a diabetes diagnosis before 40 years of age, is rising globally and associated with an aggressive disease course and early complications. This review examines the role of digital health technologies (DHT) in addressing the unique clinical and life-course challenges of EOT2D. Recent Findings: DHT, including continuous glucose monitoring, mobile health applications, digital therapeutics, telemedicine, remote patient monitoring, wearable devices, and artificial intelligence–based analytics, have demonstrated modest improvements in glycemic control, weight management, and patient engagement in people with type 2 diabetes. However, evidence in adults with EOT2D remains limited. Compared with usual-onset T2D, people with EOT2D may derive particular benefits due to higher digital literacy, greater lifestyle variability, and longer anticipated disease duration. Summary: Although DHT shows promise for improving empowerment and care integration in EOT2D, important gaps persist, including a lack of EOT2D-specific trials, digital divide–related inequities, interoperability challenges, and reimbursement barriers. Future research should prioritize tailored interventions and hybrid care models to optimize long-term outcomes in this high-risk population.

Overview

CoChat Summary

TL;DR

This narrative review examines digital health technologies (DHT) for early-onset type 2 diabetes (EOT2D), defined as diagnosis before age 40, and argues they may improve empowerment and care integration while evidence specific to EOT2D remains limited. It reviews CGM, wearables/IoT, mHealth/digital therapeutics, telemedicine/remote monitoring, and AI, and calls for tailored trials and hybrid care models.

Key findings

  • EOT2D is aggressive: compared with usual-onset T2D, people with EOT2D have 0.5–1.0% higher HbA1c at diagnosis, greater obesity and hypertension burden, and a 2–3-fold higher risk of microvascular and macrovascular complications at any given age; each 10-year earlier diagnosis confers 20–30% higher relative risk of major vascular events and death. Global incidence of T2D among ages 10–24 rose from 56 per 100,000 in 1990 to 123.9 per 100,000 in 2021, with nearly 80% of EOT2D cases in low- and middle-income countries.
  • CGM evidence in general T2D is modest: a 2024 meta-analysis of 12 RCTs reported 0.3%–0.4% HbA1c reduction and 6% improvement in time-in-range. In EOT2D/youth studies, a 12-week pilot RCT (n=28) found feasible/acceptable CGM use but no short-term HbA1c benefit and common skin issues; a 12-month cohort of publicly insured youth (n=30) found CGM use declined, HbA1c remained high, and TIR fell over time.
  • mHealth/DTx and remote monitoring show promise but are not EOT2D-specific: a 2024 systematic review of 28 digital interventions (23 RCTs) in adults with T2D found improvements in HbA1c, diet, and physical activity; the Virta remote care model achieved mean HbA1c reduction of 1.3% (7.6% to 6.3%) and 12% weight loss at 1 year, sustained at 2 years, but the population was not restricted to EOT2D. A 2022 meta-analysis of 20 RCTs found RPM lowered HbA1c by 0.4% over 6 months, and a large RPM program reported 63% of participants with poor baseline control reached target glucose or HbA1c.
  • AI and wearables are promising but understudied in EOT2D: wearable interventions in adults with T2D increase daily steps and often improve systolic blood pressure and weight, with small favorable glycemic effects; multimodal deep learning models can forecast interstitial glucose 15–60 min ahead. However, there is a lack of interventional wearable/IoT studies specifically in EOT2D and no robust hard-endpoint data; TODAY/TODAY2 showed up to 60% of youth-onset participants developed at least one microvascular complication by mean diabetes duration of 13 years.

Methods

  • Narrative review of DHT for EOT2D; the authors searched PubMed covering the past five years (2021–2025) using keywords such as “type 2 diabetes,” “digital therapies,” “mobile applications,” “mobile health,” “telemedicine,” and “self-management,” prioritizing studies that described structured digital interventions and reported clinical or patient-relevant outcomes.
  • Synthesizes evidence across five DHT categories: continuous glucose monitoring, wearable devices and IoT, mHealth applications and digital therapeutics, telemedicine and remote patient monitoring, and artificial intelligence/predictive modeling; includes Table 1 of clinical studies and two figures.
  • No new primary data are presented; evidence includes randomized trials, meta-analyses, cohort studies, qualitative studies, and reviews, with many studies conducted in general T2D or prediabetes rather than EOT2D.

Limitations

  • The paper states that evidence in adults with EOT2D remains limited, EOT2D-specific trials are lacking, CGM studies in EOT2D have small sample sizes, and there are no robust data on hard clinical endpoints such as hospitalization, cardiovascular-kidney events, or mortality in this population.
  • The paper also states implementation barriers: digital divide–related inequities, poor interoperability and lack of unified data standards, insufficient integration with electronic health records, reimbursement and regulatory uncertainty, and attenuation of intervention effectiveness over time.
  • Evident from the text: as a narrative review, it does not report a systematic search protocol, PRISMA flow, or formal quality/risk-of-bias appraisal; many cited studies are in general T2D, prediabetes, or non-EOT2D populations, and some key evidence is non-randomized or pilot/feasibility in design.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11892-026-01633-6

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 The Multifaceted Management Challenges of Early-Onset Type 2 Diabetes. CGM, continuous glucose monitoring; CVD, cardiovascular disease; SMBG, self-monitoring blood glucose
Fig. 1 The Multifaceted Management Challenges of Early-Onset Type 2 Diabetes. CGM, continuous glucose monitoring; CVD, cardiovascular disease; SMBG, self-monitoring blood glucoseCC BY · PubMed Central
Fig. 2 A Framework for Digital Health Management of Early-Onset Type 2 Diabetes. This framework of Digital Health Management in EOT2D comprises 5 distinct Digital Health Technologies (DHT). These DHTs work synergistically to provide high-quality, interoperable, and tiered digital care models for EOT2D patients
Fig. 2 A Framework for Digital Health Management of Early-Onset Type 2 Diabetes. This framework of Digital Health Management in EOT2D comprises 5 distinct Digital Health Technologies (DHT). These DHTs work synergistically to provide high-quality, interoperable, and tiered digital care models for EOT2D patientsCC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 3 Not valid · 68 Not checked · 25 Own results and interpretations

36 more claims

Create a free account to see all 96 claims and to verify the 111 references still open.

See all claims — free account
  • It may state two separate claims as one. 43
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 81 references

Research works printed but not linked: 1

  1. Berthoumieux A, Linke SE, Merry M, Megliola A, Juusola J, Napoleone J. Long-term results of a digital diabetes self-management and education support program among adults with type 2 diabetes: A retrospective cohort study. Sci Diabetes Self-Management Care. 2024;50(1):19–31. · DOI · Paper page

Cited by

Still being checked.

Metadata

Authors
Guo, L.-J., Low, K.-S., Tae, S.-K., & Lim, L.-L.
Affiliations
  • University of Malaya (MY)
  • Baker Heart and Diabetes Institute (AU)
Corresponding author
  • Tae, Sok-Kun
  • Lim, Lee-Ling
Venue
Current Diabetes Reports
Published
2026-07-10
Volume
26
Issue
1
Pages
20
ISSN
  • 1534-4827 (ISSN-L)
  • 1539-0829
OpenAlex
W7167899948
Cited by
0
References
81
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Current Diabetes Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Universiti Malaya
Topics
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
early-onset type 2 diabetes, digital health technologies, continuous glucose monitoring, mobile health apps, digital therapeutics, telemedicine, remote patient monitoring, wearable devices, artificial intelligence, glycemic control, weight management, patient empowerment, digital divide, interoperability, reimbursement barriers, hybrid care model, digital literacy
MeSH terms
Continuous Glucose Monitoring, Digital Health, Remote Patient Monitoring, Diabetes Mellitus, Type 2, Humans, Blood Glucose Self-Monitoring, Telemedicine, Age of Onset

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Digital Management of Early-Onset Type 2 Diabetes: Empowerment, Challenges, and Future Outlook. https://app.cochat.ai/papers/10.1007/s11892-026-01633-6
The paper
Guo, L.-J., Low, K.-S., Tae, S.-K., & Lim, L.-L. (2026). Digital Management of Early-Onset Type 2 Diabetes: Empowerment, Challenges, and Future Outlook. Current Diabetes Reports. https://doi.org/10.1007/s11892-026-01633-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.